CRF Health Launches TrialMax ConMed™ Solution to Capture Concomitant Medication Data Directly from Patients

Plymouth Meeting, PA – June 15, 2015:  CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, today announced the introduction of TrialMax ConMed™, an eDiary-based solution designed to enhance the real-time collection of concomitant medication data from patients in clinical trials. Today, sponsors commonly wait for a patient's site visit in order to enter concomitant medication data into electronic data capture (EDC) systems. This can be problematic as it relies on the patient's ability to recall all the different medications and doses they have taken between visits. TrialMax ConMed makes it simple for patients to report medications that they are taking alongside a study drug in real-time. The intuitive solution not only enhances patient safety and the accuracy of the resulting regulatory submission, but will ensure sites and sponsors achieve high-quality information on a patient's complete medication list for the duration of a clinical trial.

Although difficult to capture, accurate concomitant medication data is increasingly required by regulators for a more complete assessment of the study drug. For example, if an oncology study requires the identification of any pain medication that a patient is taking, patients need to be able to provide their clinician with information on any prescribed and over-the-counter pharmaceuticals that they use. TrialMax ConMed allows patients to select from a predefined list of commonly taken medications or enter a new drug into their TrialMax Touch® eDiary electronically. With access to TrialManager®, CRF Health’s online patient management portal, investigators are alerted to new medication entries to allow them to assess the completeness and accuracy of the data and correct as appropriate. Easy-to-use for both sites and patients, TrialMax ConMed ensures users remain compliant and continue to input new medication details throughout a study.